Puma biotechnology, inc. (PBYI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Sep'11Jun'11Sep'10Jun'10
Revenue:
Total revenue

51,217

62,922

56,352

53,919

99,067

71,079

62,629

50,767

66,516

-

6,077

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

Operating costs and expenses:
Cost of sales

9,076

10,142

9,371

9,317

7,985

10,359

9,048

8,831

6,383

-

1,526

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

30,937

31,257

31,402

33,527

45,506

40,949

28,502

40,135

36,602

30,874

32,489

24,929

18,401

16,472

14,022

12,265

11,039

9,596

8,809

5,532

7,871

8,062

3,867

3,904

3,525

2,983

2,263

2,267

2,274

13,665

8,094

1,771

1,284

333

34

-

2

Research and development

25,455

30,241

30,027

36,855

35,728

38,324

36,360

43,245

46,925

50,254

49,502

53,253

54,801

56,398

51,977

54,216

60,207

52,439

51,924

59,381

44,728

39,530

32,092

35,001

16,294

13,006

12,068

10,440

9,532

8,283

17,779

13,006

10,568

-

-

-

-

Total operating costs and expenses

65,468

71,640

70,800

79,699

89,219

89,632

73,910

92,211

89,910

85,174

83,517

78,182

73,202

72,870

65,999

66,481

71,246

62,035

60,733

64,913

52,599

47,592

35,959

38,905

19,819

15,989

14,331

12,707

11,806

21,948

25,873

14,777

11,852

333

34

6

-

(Loss) profit from operations

-14,251

-8,718

-14,448

-25,780

9,848

-18,553

-11,281

-41,444

-23,394

-63,566

-77,440

-78,182

-73,202

-72,870

-65,999

-66,481

-71,246

-62,035

-60,733

-64,913

-52,599

-47,592

-35,959

-38,905

-19,819

-15,989

-14,331

-12,707

-11,806

-21,948

-25,873

-14,777

-11,852

-333

-34

-6

-

Other income (expenses):
Interest income

386

498

569

908

872

703

590

329

174

221

305

380

350

202

214

260

282

317

318

213

123

101

111

66

46

44

9

96

23

35

14

23

26

-

-

-

-

Interest expense

3,068

3,076

3,052

4,448

4,443

3,820

3,499

2,587

1,079

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Legal verdict expense

93

0

0

0

16,350

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on debt extinguishment

-

-

-

-8,103

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expenses)

93

97

46

-1

-14

-24

-11

-633

-46

-13

-45

-30

-13

7

4

-376

-8

-1

-2

6

22

8

4

-5

-21

-1

39

-39

3

-

-

-

-

-13

-

-

-

Total other expenses

-2,682

-2,481

-2,437

-11,644

-19,935

-12,141

-2,920

-2,891

-951

-512

260

350

337

209

218

-116

274

316

316

219

145

109

115

61

25

43

48

57

26

35

14

23

26

-13

-

-

-

Net loss

-16,900

-11,213

-16,900

-37,400

-10,087

-30,694

-14,201

-44,335

-24,345

-64,078

-77,180

-77,832

-72,865

-72,661

-65,781

-66,597

-70,972

-61,719

-60,417

-64,694

-52,454

-47,483

-35,844

-38,844

-19,794

-15,946

-14,283

-12,650

-11,780

-21,913

-25,859

-14,754

-11,826

-347

-34

-6

-2

Net loss applicable to common stockholders

-16,933

-11,199

-16,885

-37,424

-10,087

-30,694

-14,201

-44,335

-24,345

-64,078

-77,180

-77,832

-72,865

-72,661

-65,781

-66,597

-70,972

-61,719

-60,417

-64,694

-52,454

-47,483

-35,844

-38,844

-19,794

-15,946

-14,283

-12,650

-11,780

-21,913

-25,859

-14,754

-11,826

-347

-34

-6

-

Weighted-average number of shares outstanding - basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

Net loss per share of common stock—basic and diluted

-0.43

-0.28

-0.44

-0.97

-0.26

-0.80

-0.37

-1.17

-0.65

-1.71

-2.07

-2.10

-1.97

-2.03

-2.02

-2.05

-2.19

-1.91

-1.87

-2.01

-1.66

-1.58

-1.19

-1.29

-0.67

-0.55

-0.50

-0.44

-0.41

-0.80

-1.29

-0.74

-0.59

-0.09

-0.00

-0.00

0.00

Weighted-average shares of common stock outstanding—basic and diluted

39,291

39,051

38,893

38,647

38,481

38,207

38,043

37,819

37,699

37,541

37,214

36,992

36,931

35,711

32,497

32,493

32,478

32,454

32,303

32,158

31,588

30,241

30,117

30,117

29,567

28,750

28,682

28,676

28,676

26,783

20,040

20,040

20,040

4,000

4,000

4,000

-

Product Revenue, Net
Total revenue

48,609

58,706

53,482

53,864

45,567

61,079

52,629

50,767

36,016

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License Revenue
Total revenue

2,000

4,000

2,750

0

53,500

10,000

10,000

0

30,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty Revenue
Total revenue

608

-

120

55

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-